Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes.
Isolated diastolic dysfunction is found in almost half of asymptomatic patients with well-controlled diabetes and may precede diastolic heart failure. However, mechanisms that underlie diastolic dysfunction during diabetes are not well understood. We tested the hypothesis that isolated diastolic dysfunction is associated with impaired myocardial Ca(2+) handling during type 1 diabetes. Streptozotocin-induced diabetic rats were compared with age-matched placebo-treated rats. Global left ventricular myocardial performance and systolic function were preserved in diabetic animals. Diabetes-induced diastolic dysfunction was evident on Doppler flow imaging, based on the altered patterns of mitral inflow and pulmonary venous flows. In isolated ventricular myocytes, diabetes resulted in significant prolongation of action potential duration compared with controls, with afterdepolarizations occurring in diabetic myocytes (P < 0.05). Sustained outward K(+) current and peak outward component of the inward rectifier were reduced in diabetic myocytes, while transient outward current was increased. There was no significant change in L-type Ca(2+) current; however, Ca(2+) transient amplitude was reduced and transient decay was prolonged by 38% in diabetic compared with control myocytes (P < 0.05). Sarcoplasmic reticulum Ca(2+) load (estimated by measuring the integral of caffeine-evoked Na(+)-Ca(2+) exchanger current and Ca(2+) transient amplitudes) was reduced by approximately 50% in diabetic myocytes (P < 0.05). In permeabilized myocytes, Ca(2+) spark amplitude and frequency were reduced by 34 and 20%, respectively, in diabetic compared with control myocytes (P < 0.05). Sarco(endo)plasmic reticulum Ca(2+)-ATPase-2a protein levels were decreased during diabetes. These data suggest that in vitro impairment of Ca(2+) reuptake during myocyte relaxation contributes to in vivo diastolic dysfunction, with preserved global systolic function, during diabetes.
Lacombe
Véronique A
VA
College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Viatchenko-Karpinski
Serge
S
Terentyev
Dmitry
D
Sridhar
Arun
A
Emani
Sitaramesh
S
Bonagura
John D
JD
Feldman
David S
DS
Györke
Sandor
S
Carnes
Cynthia A
CA
D000200:Action Potentials / Q000502:physiology; D000818:Animals; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism* / Q000502:physiology; D020746:Calcium Channels, L-Type / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000378:metabolism* / Q000503:physiopathology; D003971:Diastole / Q000502:physiology; D004562:Electrocardiography; D006352:Heart Ventricles / Q000166:cytology / Q000378:metabolism; D008297:Male; D032342:Muscle Cells / Q000378:metabolism*; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012519:Sarcoplasmic Reticulum / Q000378:metabolism; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000378:metabolism
D020746:Calcium Channels, L-Type; D015221:Potassium Channels; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D002118:Calcium